INTRODUCTION
passive external stretch is related to NO release from the endothelium (7 -9) , On the other hand, phenylephrine induces NO release by α2 receptor in endothelium cells (10) , in addition to direct contraction effect on smooth muscle. These NO-releasing systems of the vasculature is considered to function as a kind of self-protecting mechanism against excessive force generation by vascular smooth muscle cells (7) . However, whether hypertensive effect of L-DOPA is related with NO signaling pathway is unknown. In this study, we investigated the mechanism of effect of L -DOPA on phenylephrine -induced contractile force of blood vessels in vitro by using several pharmacological blockers The results indicate that the effect of L-DOPA on contractile force of blood vessels was mediated by NO signaling pathway via production of reactive oxygen species.
METHODS

Agents
Phenylephrine(phe), acetylcholine(Ach), sodium nitroprusside (SNP), S-nitroso-N-acetyl -penicillamine (SNAP), L-3,4-dihydroxyphenylalanine(L-DOPA), Nω -Nitro-L-arginine (L-NNA), 8-(4 -chlorophenylthio) guanosine 3' 5'-cyclic monophosphate (cpt-cGMP) , 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1), superoxide dismutase (SOD) and indomethacin were purchased from Sigma (St. Louis, MO, USA).
Preparation of aortic rings and tension measurement
All animal procedures were in accordance with the institutional guidelines for the care and use of laboratory animals of Tokushima University. Male Wistar rats (Japan SLC, Shizuoka, Japan) weighing 150-250 g were anesthetized by an intraperitoneal injection of pentobarbital. The thoracic aortas were dissected free of connective tissue and cut into ring segments, 3-to 4-mm in length. In some experiments, the aortic endothelium was removed by inserting a cotton thread into the lumen followed by gentle rubbing. Each ring was then placed in a 3 ml organ bath (Micro Easy Magnus, Kishimoto Medical ; Kyoto, Japan) and mounted on two stainless steel wires, one of which was fastened to the bath and the other connected to a force transducer for the measurement of isometric tension. The bath was filled with Krebs-Ringer bicarbonate buffer (KRB) solution at 37! !and bubbled with a mixture of 95% O2-5% CO2. The KRB contained (in mmol/L) 118 NaCl, 4.6 KCl, 2.5 CaCl2, 24.8 NaHCO3, 1.2 MgSO4, 1.2 KH2PO4, and 5.6 glucose. The ring was equilibrated for 60 mins under a resting tension of 1.5 g and the solution was changed at 30 min intervals. The presence or absence of endothelium was confirmed by the addition of the endothelium-dependent vasodilator, acetylcholine (10 -6 M), after contractions had been induced by phenylephrine (α1-adrenergic receptor agonist) (10 -6 M). Following washout of phenylephrine and acetylcholine with KRB, the aortic rings were contracted by adding a solution to the bath with a high K + concentration (50 mM KCl). After recording the contractile force of each ring in response to high K + , the KCl was washed out with KRB. Each ring was then allowed to equilibrate at a resting tension of 1.5 g for 20 min. The contractile response in the test experiments described below was expressed relative to that measured for the KClinduced contraction (1 st KCl) (11, 12) .
Preparation of rat smooth muscle cells
Isolation of vascular smooth muscle cells from rats was conducted as described previously (13) . Briefly, male Wistar rats aged 8 to 10 weeks were anesthetized with ether, and 1.0 U/g heparin was injected into the peritoneal cavity 30 min before surgery. Aortas were dissected and longitudinally opened in the longitudinal direction, and endothelium and adventitia were removed. The tissue was then minced into small pieces in normal Tyrode's solution. The pieces were then explanted on glass coverslips in tissue culture dishes filled with medium 199 (Nissui Chemicals, Tokyo, Japan), supplemented with 10% fetal bovine serum (GIBCO, Grand Island, NY), 100 μg/ml streptomycin, and 100 μg/ml penicillin and stored in a carbon dioxide incubator (5% CO2, 37! !). Single smooth muscle cells migrated out of the tissues and adhered to the coverslips within a few days. After culturing for 6-10 days, they were used in the experiments described below.
Effect of L-DOPA on aortic ring contraction
Test experiments involving L-DOPA were conducted on aortic rings in which contraction was induced by either phenylephrine (10 -9 -10 -4.5 M) or KCl (30, 50, or 80 mM). L-DOPA (10 -7 to 10 -4.5 M) was added to the incubation system either 20 min prior to or during the contraction induced by each constrictor. Vehicle (water)-treated rings were used as controls.
NO synthesis Inhibitor treatment of aortic rings
In some experiments, endothelium-derived nitric oxide (NO) or prostaglandins were blocked by incubating aortic rings with L-NNA (3! 10 -5 M) or indomethacin (10 -5 M) to inhibit NO or prostaglandin synthesis, respectively. The aortic rings were pretreated with each inhibitor for 20 min and then contraction was induced by phenylephrine or KCl. Each inhibitor was present in the incubation system during contraction.
Determination of L-DOPA-inhibited endotheliumdependent aortic relaxation
In the experiment of effect of SNP, cpt-cGMP or acetylcholine, SNP (NO donor ; 10 -11 -10 -6 M) or cptcGMP (10 -9 -10 -4 M) were added to the bath during the contraction induced by phenylephrine (10 -5 M) or KCl (50 mM). In other experiments, acetylcholine (10 -6 M)-induced vasorelaxation was assessed in aortic rings that had been contracted by phenylephrine (10 -5 M).
Effect of YC-1 on L-DOPA-inhibited relaxation of aortic rings
Aortic rings without endothelium pretreated with L-DOPA (10 -5 M) for 20 mins and then induced contraction by phenylephrine (10 -5 M). YC-1(0.1-100 uM) per 10 mins added into the bath with the subsequent contraction by phenylephrine. Vehicle (water)-treated rings were used as controls.
Effect of SOD on L-DOPA-inhibited endotheliumdependent relaxation of aortic rings
Aortic rings with endothelium were pretreated with SOD (150 U/ml) for 20 mins and then induced contraction by phenylephrine (10 -5 M). L-DOPA (10 -7 -10 -4.5 M) were added to the bath after induced contraction. Vehicle (water)-treated rings were used as controls.
Measurement of intracellular cGMP
The rat smooth muscle cells cultured in a 35 mm dish were treated with or without L-DOPA (10 -5 M) in the Krebs-Ringer Hepes buffer solution (containing 125 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 2.6 mM MgSO4, and 5 mM Hepes, pH 7.4) for 5 min at 37" !. Cells were then stimulated with SNAP (1, 10, or 100 M) for 5 mins. Following washing two times with ice-cold phosphate-buffered saline, intracellular cGMP was extracted with 1 ml of HCl (0.1 M) under shaking for 20 minutes at room temperature. 
Statistical analysis
Data are expressed as the mean"S.D. and were analyzed by ANOVA plus Bonferroni multiple comparison tests. A P-value!0.05 was regarded as statistically significant.
RESULTS
L-DOPA potentiated phenylephrine-induced contraction through endothelium-and NO-dependent pathways
Firstly, we examined the effect of L-DOPA on vascular contraction using rat aortic rings precontracted by phenylephrine ( Fig. 1-a) . Fig. 1-b showed a trace demonstrating the effect of L-DOPA on rat aortic rings pretreated with phenylephrine. As shown in Fig. 1 -c, administration of L-DOPA alone to the rings without phenylephrine (vehicle group) did not induce contraction. However, when the rings were precontracted by phenylephrine, subsequent administration of L-DOPA potentiated contraction in a dose-dependent manner. After washed with KRB, the contractile effect of the rings caused by L-DOPA disappeared and L-DOPA retreatment restored rat aortic ring contraction to phenylephrine precontraction state. This effect of L-DOPA was not affected by pretreatment of the rings with indomethacin (10 -5 M), an inhibitor of prostaglandin synthesis ( Fig. 1-c) . In contrast, pretreatment of the rings with L-NNA (3! 10 -5 M), an inhibitor of NO synthesis, or the removal of endothelium from the rings ( Fig. 1-d ) significantly inhibited the L-DOPA -mediated increase in contractile force. Dopamine and its metabolite, DOPAC (L-3,4 -dihydroxyphenylacetic -acid), failed to enhance the phenylephrine-induced aortic contraction when these substances were used at concentrations up to 10 -5 M (data not shown).
To examine the effect of L-DOPA pretreatment on subsequent phenylephrine-induced contraction, L-DOPA (10 -5 M) was administrated 20 min prior to phenylephrine (10 -9 -10 -4.5 M) ( with intact endothelium. It is well known that the blockade of endothelium-derived NO or removal of endothelium itself induces hypercontractility of blood vessels (11) . L-DOPA pretreatment did not further increase contractile force in these NOblocked and endothelium-denuded aortic rings ( Fig.  2c and d) . These results suggest that L-DOPA potentiated phenylephrine-induced aortic contraction through endothelium-and NO-dependent pathways.
We also examined the effect of L-DOPA on depolarization-induced contraction of rat aortic rings precontracted by KCl (50 mM). Administration of L-DOPA during KCl-induced contraction increased contractile force in a dose-dependent manner. This effect of L-DOPA was almost completely inhibited by pretreatment of the rings with L-NNA (3! 10 
L-DOPA inhibited endothelium-dependent relaxation of the aorta
Next, we tested whether potentiation of L-DOPA is due to inhibition of endothelium-dependent relaxation by NO signal. The effect of L-DOPA on endothelium-dependent vasorelaxation was examined using aortic rings which had been precontracted by phenylephrine (Fig. 3-a) . As shown in Fig. 3-b , acetylcholine (10 -6 M) almost completely relaxed the tension in aortic ring with intact endothelium.
Since acetylcholine -induced vasorelaxation depends largely on endothelium-derived NO in conduit arteries (14) , this relaxation was inhibited by pretreatment with L-NNA (Fig. 3-c) . L-DOPA pretreatment also inhibited acetylcholine-induced vasorelaxation to the same extent as that observed in the L-NNA-treated rings (Fig. 3-c) .
L-DOPA inhibited exogenous NO-dependent but not cGMP-mediated vasorelaxation
NO activates guanylate cyclase which in turn increases the concentration of intracellular cGMP in the smooth muscle cells (15) . The rise of cGMP levels triggers subsequent vasorelaxation (15) . To further study the mechanism of L-DOPA, we tested the effect of L-DOPA on cGMP induced vasorelaxation using the membrane-permeable cGMP analog, cpt-cGMP. Endothelium-denuded aortic rings were first precontracted by phenylephrine or KCl ( 4 -a), and after the contraction reached a steady level, subsequent relaxing responses induced by cpt-cGMP (10 -9 -10 -4 M) were assessed in the presence or absence of L-DOPA (10 -5 M). L-DOPA pretreatment failed to affect cpt-cGMP-mediated vasorelaxation in the rings contracted with phenylephrine (Fig. 4-b) or KCl- (Fig. 4-c) .
L-DOPA-inhibited vasorelaxation was not soluble guanylyl cyclase-dependent
Soluble guanylyl cyclase (sGC) expressed by endothelium of blood vessel is considered the key enzyme mediating vascular relaxation induced by NO. By the formation of cyclic GMP, this enzyme mediates NO-mediated vascular smooth muscle relaxation (16, 17) . In order to probe whether L-DOPAinhibited vasorelaxation was caused by blocking the action of soluble guanylyl cyclase, effect of YC-1 (an activator of guanylyl cyclase) (18) on the aortic ring contraction was examined. In aortic rings without endothelium pretreatmented with L-DOPA (10 -5 M), YC-1was added into the bath and subsequent contraction effect of rings by phenylephrine was studied ( Fig. 5-a) . YC-1 (0.1 μM-100 μM) could relax the rings precontracted by phenylephrine in dosedependent manner. There was no significant difference in relaxation between the ring with and without pretreatment by L-DOPA (Fig. 5-b) , suggesting that solube guanylyl cyclase is not a target of L-DOPA-inhibited vasorelaxation. Similar effect was observed in the experiment using atrial natriuretic peptide, an activator of membrane guanylyl cyclases (data not shown).
L-DOPA attenuates NO-donor-induced cGMP production in cultured rat aortic smooth muscle cells and inhibits acetylcholine-induced relaxation
To examine whether L-DOPA affects cGMP production by NO, cultured rat aortic smooth muscle cells were stimulated with a donor of NO, SNAP (1-100 μM), and intracellular cGMP levels were measured in the presence or absence of L-DOPA (10 
L-DOPA mediated inhibition of relaxation is due to inactivation of NO by oxygen free radicals
Increased production of reactive oxygen species (ROS) reduces the effect and/or bioavailability of NO, leading to an impaired endothelial function. Through auto-oxidation, L-DOPA forms reactive free radicals such as hydroxyl radicals, oxygen free radicals. Oxygen free radicals (O2 -) can decrease ring relaxation by inactivation of NO (19, 20) . In this experiment we used SOD to decrease O2 -generation in order to further confirm NO effect in L-DOPA -mediated contraction. Aortic rings with endothelium were pretreated with SOD (150 u/ml) for 20 mins. L-DOPA (10 -7 -10 -4.5 M) were added to the bath with the subsequent contraction by phenylephrine (10 -5 M) ( Fig. 8-a) . Fig. 8-b showed that SOD (150 U/ml) pretreatment inhibited contraction by L-DOPA of rings with endothelium.
DISCUSSION
Our present studies indicated that L -DOPA increased the α-adrenergic receptor-mediated and depolarization-induced vascular contraction and decreased ACh-induced vascular relaxation in endothelium-intact rat aorta, which was inhibited by L-NNA pretreatment. L-DOPA attenuated the rise in the intracellular cGMP and inhibited vasorelaxation with an NO donor, but not those with cpt-cGMP, a membrane-permeable cGMP analog, or YC-1, an activator of guanylyl cyclase, suggesting that action of L-DOPA might be upstream of guanylyl cyclase. SOD (150 U/ml) pretreatment inhibited contraction by L-DOPA of rings with endothelium, suggesting that production of reactive oxygen species by L-DOPA decreases the NO action. All these data demonstrated that the underlying mechanism of vasocontractive effect of L-DOPA was inhibition of NOdependent vasorelaxation via production of reactive oxygen species from L-DOPA. It is well know that nitric oxide (NO) is the major mediator of endothelium-dependent relaxation in aorta (15, 21, 22) , which is formed from the conversion of L-arginine by nitric oxide synthase (NOS) in endothelium cell and released. This endothelium -derived NO stimulates the activity of soluble guanylate cyclase (sGC) in smooth muscle cells, leading to an increase in cyclic guanosine-3',5'-monophosphate (cGMP) and finally to calcium depletion from the cytosolic space and vascular smooth muscle relaxation (15, (21) (22) (23) . Various agonists such as NE (noradrenaline), phenylephrine, 5HT can stimulate the release of NO from the endothelium during vasocontractile response to them (9) . In our present study, we found that L-DOPA increased the phenylephrine (α1-adrenergic receptor)-mediated and depolarization-induced vascular contraction in endotheliumintact rat aorta, which was inhibited by L-NNA pretreatment, suggesting this reaction is mediated by NO pathway. Meanwhile, we also found that L-DOPA pretreatment inhibited acetylcholine-induced vasorelaxation. The acetylcholine-induced vasorelaxation is largely mediated by endothelium-derived NO in conduit arteris (9) . Effect of NO is mainly mediated by production of cGMP. Thus, we studied the effect of L-DOPA on cGMP. L-DOPA could not reduced relaxation by cGMP, such as membrane permeable cGMP (cpt-cGMP), or soluble guanylate cyclase activator (YC-1), suggesting that the intracellular signaling pathway downstream from cGMP would not contribute this mechanism. Nakatsubo et al. also found that L-DOPA decreased fluorescence levels of diaminofluorescein-2 (DAF-2), a widely used indicator of NO (24) . In our preliminary study, L-DOPA decreased nitroprusside-induced fluorescence levels of DAF-2 in the presence of an NO donor in cell-free system (data not shown). This hypothesis is also supported by our data that SOD pretreatment of rings with endothelium induced the subsequent ring relaxation.
L-DOPA is molecularly unstable and can rapidly auto-oxidize in the presence of oxygen or light and oxidize enzymatically to yield free radicals : semiquinones, O-quinone derivatives and several free radicals such as hydrogen peroxide (H2O2 -) and superoxide (O2 -). Rocchitta et al. (25) reported that autooxidation of exogenous L-DOPA occurs in vivo in the extracellular compartment of the freely moving rat with a consequent formation of L-DOPA semiquinone (L-DOPA-SQ) in dialysates. NO reacting with superoxide generates peroxynitrite (O=NOO -) to block NO signaling pathway by inactivating NO (20, 26, 27) , leading to decrease of ring relaxation (12, 13) . L-DOPA is transported into mammalian cells through the L-type amino acid transporter 1 (LAT1) (13) , which is also expressed in vascular endothelium (28) . In vitro experiments showed that L-DOPA can lead to accumulation of O2 -, and the addition of SOD resulted in higher levels of NO2
- (27) . In vivo experiment also revealed that SOD can completely inhibit L-DOPA auto-oxidation (20) and decrease spontaneous tone in endothelium-intact rings by scavenging O2
-and thereby freeing endotheliumderived NO to relax the blood vessel (29) . Therefore, we concluded that L-DOPA mediated inhibition of relaxation is due to inactivation of NO by oxygen free radicals. We do not know whether L-DOPA could produce vasoconstriction via production of reactive oxygen species in vivo, because in vivo endogenous antioxidants, such as ascorbic acid or Vitamin E. Further investigation is needed to clarify in vivo effect of L-DOPA.
MAO-A/B mixed inhibitors may be efficacious in the inhibition of dopamine metabolism and the treatment of PD (30, 32) , but there are some side effects of increasing the blood pressure in the presence of a non-selective monoamine oxidase (MAO)-A/B inhibitor or a selective MAO-A inhibitor, L-DOPA increased blood pressure in both PD patients and rats (4, 33) . These results indicate that L-DOPA exerts directly on its vasoconstrictive effect without conversion to dopamine.
Minimizing the side effects of hypertension by L-DOPA treatment would be necessary for the maintenance of physical as well as mental well-being of PD patients. The NO-inhibiting effect of L-DOPA on the vasculature could be applicable to the establishment of a novel therapeutic strategy for the treatment of cardiovascular disorders in PD patients. The concentration of L-DOPA used in the present study (mainly 10 -5 M) is near the plasma concentration in L-DOPA-treated PD patients (approximately 0.5-1.0! 10 -5 M) (34) . Thus, L-DOPA at this concentration is considered to be enough to inhibit the NO pathway in these patients. From our study, however, in the absence of vasoconstrictors, L-DOPA did not induce contraction of rat aortic rings and the effect of L-DOPA on blood pressure in PD patients was also complex. L-DOPA-mediated inhibition of the NO pathway would result in vasoconstriction when endothelial production of NO was high. However, vasoconstriction due to NO inhibition might be offset by an L-DOPA-mediated sympathetic inhibition. Thus, further studies are needed to clarify the interaction of these different mechanisms on the regulation of the cardiovascular system in PD patients treated with L-DOPA. All together, our experimental results revealed the mechanism about hypertensive effect of L-DOPA and provided a new possibility to the establishment of a novel therapeutic strategy for the treatment of PD patients to avoid side effects (e.g. hypertension) caused by therapy.
